Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 4

Sponsor Class

NIH 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 2

Conditions

Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Cyclophosphamide 388Specimen Handling 377Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × tandutinib × Clear all
NCT00408902 2017-11-22

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

NCT00379080 2017-04-07

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
60 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00390468 2014-05-28

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 5 charts
Genitourinary

Neoplasm Metastasis, Pain, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡